Vesatolimod (GS-9620) is an effective, selective, oral toll-like receptor 7 (TLR7) agonist with an EC50 value of 291 nM. Vesatolimod (GS-9620) rapidly internalizes into cells and preferentially localizes to and signals from endo-lysosomal compartments.
In vivo, single oral doses of Vesatolimod (GS-9620) at 0.3 and 1 mg/kg in uninfected chimpanzees demonstrates a dose- and exposure-related induction of serum IFN-α, select cytokines/chemokines, and IFN-stimulated genes (ISG) in the peripheral blood and liver.
Molecular Weight | 410.51 |
Formula | C22H30N6O2 |
CAS Number | 1228585-88-3 |
Solubility (25°C) | DMSO 15 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[4] Indrani Rebbapragada, et al. Molecular Determinants of GS-9620-Dependent TLR7 Activation
Related TLR Products |
---|
Kdo2-Lipid A ammonium
Kdo2-Lipid A ammonium is a chemically defined lipopolysaccharide (LPS) with endotoxic activity equivalent to LPS.Kdo2-Lipid A ammonium is highly selective for TLR4 and stimulates the release of TNF and PGE2. |
PSMα3
PSMα3 is a peptide for manipulating DCs to become tolerogenic for DC vaccination strategies. |
Pam2CSK4
Pam2CSK4, a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. |
MAPK-IN-1
MAPK-IN-1 is a MAPK signaling pathway inhibitor. |
Cobitolimod
Cobitolimod is a first-of-its-kind (first-in-class), synthetic oligodeoxynucleotide (ODN) containing unmethylated CpG motifs that activates TLR9 in specific cells, including intestinal T and B lymphocytes as well as antigen-presenting cells (APCs), and can be used in studies related to inflammatory bowel disease (IBD). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.